Cardiovascular Specialist covering Alabama and Mississippi
Birmingham, AL
Joined October 2020
- Tweets216
- Following421
- Followers110
- Likes985
Alex Matthews retweeted
Out of my last 60 open cases, 5 have involved a TAVR excision for various reasons. TAVR removal is by far the most common “new” operation that I have been asked to perform in the last year, with a meteoric rise compared to years past. Are others having a similar experience?
Alex Matthews retweeted
Agree with you 100%. This is a 7 year old Inspiris removed from a woman in her 60s last year.
If you read the 10 year COMMENCE data you would think that nothing ever happens to this valve. The correct way of doing that study would have been to double blind it with a Magna.
#inspiris implanted 6 years ago. There is very little clinical data to suggest this valve will be as durable as it's predecessor, Magna or MagnaEase. But certainly more expensive. @tomcnguyen @DrZeigler1 @Abedeanda @APolancoMD
Alex Matthews retweeted
Mean time to redo-TAVI 6 years. That means a 70 year old patient will get TAVI at 70, TAVI in TAVI at 76, TAVI in TAVI in TSVI at 82 (assuming same degeneration rate) and TAVI in TAVI in TAVI in TAVI at 88 ?? Am I the only one seeing this abomination ?
The number of redo-TAVI procedures is expected to rise substantially as indications expand to younger patients with aortic stenosis who are likely to outlive their index transcatheter heart valve. The ReTAVI registry represents the first prospective, multicentre evaluation of redo-TAVI providing systematically collected, core lab-adjudicated data on procedural feasibility and early outcomes. eurointervention.pcronline.c…
Alex Matthews retweeted
Today, our team continues to push the boundaries of aortic care with Drs. Parodi, Bozso, & Frederick.
✅ First in the USA to offer the Artivion NEXUS Total Arch Device after FDA approval
✅ Expanding one of the nation’s leading aortic programs
✅ Training the next generation
Alex Matthews retweeted
We are proud to announce that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire our company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for open surgical repair.
You can read the full press release and learn more here: businesswire.com/news/home/2…
#NEXUSaorta #totalarch #aorticdissection #aorticarchrepair #aortaEd
Alex Matthews retweeted
Endospan’s Nexus Aortic Arch Stent Graft System Approved by FDA | @EndospanLtd evtoday.com/news/endospans-n…
The best aortic valve also resides in his heart!!! OnX!
heart-valve-surgery.com/vide…
Long, active lives come from thoughtful, informed decisions.
Congratulations, @CoachHoiberg!
The nation's best resides in Lincoln.
Coach Hoiberg is your Associated Press National Coach of the Year.
49
Alex Matthews retweeted
I have never seen a patient with a failing aortic bioprosthesis placed with a “root enlargement” in the past whose coronaries were high enough to qualify them for a valve-in-valve TAVI.
Alex Matthews retweeted
Fantastic start to afternoon sessions learning from the masters about addressing aortic arch pathology @STS_CTsurgery #sts2026
Alex Matthews retweeted
These studies remind me of tobacco company-sponsored studies in the 1950s that showed no early mortality differences between smokers and non-smokers.
Presented at #TCT2025:
In low-risk patients with severe aortic stenosis, transcatheter and surgical aortic-valve replacement had similar 7-year survival and valve durability outcomes, with no evidence of differences in composite end points. Full PARTNER 3 trial results: nej.md/4nieHfx
@CRFHeart
ALT Transcatheter Cardiovascular Therapeutics Original Article | Oct 27, 2025 | NEJM.org Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years Figure 1A. Death from Any Cause, Stroke, or Rehospitalization
Alex Matthews retweeted
Mark your calendars for an important webinar: Data-Driven Valve Selection for Younger AVR Patients, featuring @JordanBloomMD, @ChrisMalaisrie and @MarcGerdisch. September 25 at 8 am ET. Click here to register: bit.ly/4n4h4TP
Alex Matthews retweeted
Registration now open! Don’t miss this live webinar where experts will discuss the latest data on AVR, including the STS Database survival outcomes, On-X 5-year PAS results, and how valve selection is evolving for today’s patients.
Register Here: ow.ly/9hKS50WPIc7
Alex Matthews retweeted
Congratulations to the @uabcvi Division of Cardiothoracic Surgery for earning the @STS_CTsurgery highest quality accreditation, a distinction that places UAB Medicine among the top 1% of cardiothoracic surgery programs nationwide.👏
🔗 brnw.ch/21wVrsQ
Alex Matthews retweeted
Mechanical valves are grossly underutilized in the US. There is a solid body of literature slowly emerging to back up this claim.
Alex Matthews retweeted
The UAB Cardiovascular Institute has earned the highest caliber of quality accreditation from the Society of Thoracic Surgeons – placing UAB in the top one percent of all U.S. cardiothoracic surgery programs.
Read more about the accomplishment here: bit.ly/4mFMwHr.
Alex Matthews retweeted
Also amazing wetlab sponsored by @ArtivionInc a company truly dedicated to education and the Ross.
Alex Matthews retweeted
A bioprosthesis implanted on a young patient does not only expose them to the risk of a reoperation but more importantly to a second lifetime cycle of LV strain (aortic) or pulmonary hypertension (mitral) as well to development of endocarditis of the degenerated bioprosthesis.